

Index

A

Abnormal seminal vesicles, 448, 449
Acquired renal cystic disease, 11
Acute kidney injury, 476
ADPKD, 22, 376
Apoptosis detection, 200
Apoptosis in animal models of ADPKD, 205
Apoptosis in animal models of ARPKD, 203
Apoptosis, 150, 197, 199
Apoptotic cells, 199, 203, 205
ARPKD, 14
ARPKD-CHF, 28
Arterial hypertension, 97
Assembly of cilia, 381
Atomic force microscopy, 148
Autosomal dominant medullary cystic disease, 12
Autosomal Dominant Polycystic Kidney Disease, 3
Autosomal dominant polycystic liver disease, 13
Autosomal recessive polycystic kidney disease, 12, 23

B

Bardet-Biedl syndrome, 13
Bax, 201, 202
Bcl2, 202, 203
BET bromodomain protein, 292
Beta-catenin, 284
Bilateral parapelvic cysts, 11
Biliary ectasia, 27

Biogenesis, 259
Biological efficacy, 111
Blood pressure control, 95
Blood pressure targets, 100
Blood pressure, 114
Bone formation, 461
B-Raf, 176, 179, 183

C

Calcineurin, 181, 183
Calcium homoeostasis, 149
Calcium, 169
cAMP, 172
Cardiovascular, 401
Caroli disease, 23, 427, 429
Caspase, 207
CDK4, 183
Cell matrix alterations, 153
Cell polarity, 152
Cell proliferation, 150
Childhood PKD, 21
Chronic inflammation, 353
Cilia and cell cycle, 380
Ciliary defects, 375, 382
Ciliary function, 405
Ciliary structure, 404
Ciliary trafficking, 264, 268
Ciliogenesis, 292
Ciliopathies, 382
Cis-autoproteolytic mechanism, 261
Clinical biomarkers, 113
Clinical description, 338
Clinical features, 33
Clinical manifestations, 399
Clinical symptoms, 432

Index

Clinical trials, 109, 114

C-Myc, 231

Complement -3, 345

Congenital hepatic fibrosis, 23, 25, 27

Consultations, 67

Contiguous PKD1-TSC2 syndrome, 14

Craniofacial, 457, 464

Cyclic AMP, 149, 169

Cyst formation, 37, 38, 152, 338, 408

Cyst growth , 152, 342

Cystic disease, 172

Cystic kidney diseases, 22

Cystic kidney, 400

Cystic phenotype, 39

Cystogenesis, 235

D

Deletion of Pkd1/Pkd2, 459

Diagnosis, 25, 75, 76, 78, 402

Differential diagnosis, 3

Disease progression, 341

DNA methylation, 285, 287

Dysfunction, 397

E

EGFR, 38, 39, 40, 289

Epidemiology, 24

Epigenetic regulation, 285

Epigenetic studies, 287

Epigenetics, 283

Epigenome, 285

ERK, 179, 183

Etiology, 398

Extrarenal complications, 64

Extrinsic death receptor

pathway, 201

F

Fibrosis, 293

Fluid secretion, 152

Future therapy, 39

G

Genetic connection, 431

Genetic mutations, 76

Genetic test , 10

Genetics, 24

GFR, 112, 113

Glomerulonephritis, 471, 475, 476, 477

GPS cleavage, 264

GPS, 259

H

HALT-PKD, 101

HDAC5, 289

HDAC6, 289

Head morphology, 461

Hematuria, 400

Hepatic cysts, 430

High water intake, 118

Histone deacetylases, 287

Homeostasis, 235

Hypertension, 63, 97, 98, 99, 294

I

Immune cell infiltration, 346

Infections, 84

Infertility, 450

Inflammation in CKD, 339

Inflammation in PKD, 340

Inflammation, 152, 335

Innate immune cells, 344

Index

Intrinsic mitochondrial pathway, 202

K

Kidney development, 236

L

Life style modifications, 67
Liver cystic lesions, 426
Liver, 401, 425
Long-term monitoring, 67
Long-term tolerability, 114

M

M1 macrophages, 350
M2 macrophages, 350
Macrophage activation, 350
Macrophages, 342
Male urogenital organs, 445
Mammalian head, 458
Management, 66, 432
Mast cells, 344
Mechanical stress, 460
Mechanisms of apoptosis, 200
Mechanosensory cilia, 397
Meckel-Gruber syndrome, 14
Medullary sponge kidney, 11
Megavesicles, 447, 450
MicroRNAs, 313
miR-17, 317
miR-200, 319
miR-21, 320
miRNA-based therapy, 321
Molecular abnormalities, 76
Molecular basis, 139
Mouse models, 382
MRI, 346

mTOR inhibitors, 117
mTOR, 212, 384
Multiple benign simple cysts, 11
Myc molecular function, 234

N

Natural history, 79, 112
Nephrectomy, 82
Nephrolithiasis, 401
Nephronophytis, 14
Nephrotic syndrome, 474
NFAT, 178, 181, 182
NF-κB, 201, 202, 208, 214, 353
Niacinamide, 119, 120, 290
Nitric oxide, 410
Nocodazole, 289
Non-lymphoid cells, 351
Non-orthologous cystic mouse models, 240
Normal seminal vesicles, 446

O

Orofaciodigital syndrome type, 13
Orthologous PKD mouse models, 241

P

Pathogenesis, 197
Pathology, 26
PC1-C-terminal tail, 348
PC1-PC2 interactions, 144
PC1^U and PC1^{cFL}, 272
PH, 28
Phagocytes, 341
Phenotypic switch, 179, 180
Pkd1 mutant, 206
PKD1, 3, 139, 140
Pkd1/Pkd2 function, 463

Index

Pkd1/Pkd2 in mastication, 460
Pkd2 conditional knockout mice, 460
Pkd2 mutant, 206
PKD2, 3, 139, 140, 141
Polycystic liver disease, 429
Polycystin complex, 268 , 269
Polycystin structure, 142
Polycystin-1 cleavage, 261
Polycystin-1, 141, 259
Polycystin-2, 143, 347, 348
Polycystins, 139
Preclinical models, 110
Primary abnormality, 178
Primary apical cilium, 145, 147
Primary cilia, 378, 404, 406
Prognosis, 36
Proteinuria, 473, 474
Pulmonary insufficiency, 25, 28

R

RAAS inhibitors, 99, 100
Regulation of Myc, 233
Renal Cilia, 382
Renal cysts, 7, 13
Renal fibrosis, 152
Renal inflammation, 293
Renin-angiotensin system, 114
Roscovitine, 212

S

SBM mouse model, 238
Screening, 402
Seminal vesicle cysts, 445
Seminal vesicle ectasia, 447

Seminal vesicles, 443
SIRT1, 290
SIRT2, 292
Sirtuin, 1, 119
Small angle X ray scattering, 146
Somatostatin, 116, 403
STATs, 351
Structure of cilia, 378
Symptomatic polycystic kidney disease, 75
Symptoms, 80

T

Therapeutic strategies, 212
Therapis, 402
Therapy, 80
Three-hit model, 149
Threshold model, 149
TNFR1, 207, 208, 211
TNF- α , 201, 202, 207, 208
Tolvaptan, 81, 116
Tools to study epigenetics, 295
Trans-arterial embolization, 81
Transcription factors, 348
Trans-Golgi network, 266
Treatment, 29, 62, 75, 98, 197, 283
Triptolide, 120
Tuberous sclerosis complex, 12
Two-hit model, 149

V

Vasopressin receptor antagonists, 115
Von Hippel-Lindau syndrome, 12

Doi: http://dx.doi.org/10.15586/codon.pkd.2015.ind